"item","source","text","drug","section","gene","biomarker","pkImpact","pdImpact","drugRec","doseRec","testRec","monitRec","variant","prodrug","medicationConcern","variantFreq","clinical","medicalCondition","testResult","alleles","comment"
"urn:domeoclient:uuid:FE73DA30-2D2E-4D34-AC2F-B160599E5ADD","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02","Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. ","Letrozole","34067-9 INDICATIONS AND USAGE SECTION","ESR1, PGR","ER and PgR_receptor",,,,,,,,,,,,"MedicalCondition","biomarker-positive",,"Add drug selection recommendation of """indicated for""""
"urn:domeoclient:uuid:FE154A72-C1D3-4027-8C73-C71A948D0F52","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0","In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estrogen- and progesterone-receptor levels less than 10 fmol. In women aged 60 to 70 years, there was a trend toward a beneficial effect of tamoxifen without any clear relationship to estrogen- or progesterone-receptor status.","Tamoxifen","34092-7 CLINICAL STUDIES SECTION","ESR1, PGR","ER and PgR_receptor",,"Increased Efficacy",,,,,,,,,"Clinical Trial",,"biomarker-level-high",,
"urn:domeoclient:uuid:FC7D109F-F404-4287-BE4A-D7C5AA057401","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","CNA106030 (PREDICT-1), a randomized, double-blind study, evaluated the clinical utility of prospective HLA-B*5701 screening on the incidence of abacavir hypersensitivity reaction in abacavir-naive HIV-1-infected adults (n = 1,650). In this study, use of pre-therapy screening for the HLA-B*5701 allele and exclusion of subjects with this allele reduced the incidence of clinically suspected abacavir hypersensitivity reactions from 7.8% (66/847) to 3.4% (27/803).","Abacavir","WARNINGS AND PRECAUTIONS (43685-7)",,"HLA-B*5701",,,,,,,"HLA-B*5701",,,,,"MedicalCondition","gene-haplotype-positive",,
"urn:domeoclient:uuid:FB8FC7BE-DF14-4ABF-B790-607DABB38F49","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.","Abacavir","34066-1 BOXED WARNING SECTION","HLA-B","HLA-B*5701",,,"Discontinue/Do not restart",,,,,,,,,"MedicalCondition","gene-haplotype-negative","HLA-B*5701",
"urn:domeoclient:uuid:FB3C226D-314F-473A-AA0D-98DCD192D7AF","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status","Abacavir","34070-3 CONTRAINDICATIONS SECTION","HLA-B","HLA-B*5701",,,"Discontinue/Do not restart",,,,,,,,,"MedicalCondition","gene-haplotype-negative","HLA-B*5701",
"urn:domeoclient:uuid:FB17C9EA-111C-4784-80AC-30417D974CE8","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd","TPMT genotyping or phenotyping (red blood cell TPMT activity) can help identify patients who are at an increased risk for developing azathioprine tablets toxicity.2, 3, 7, 8, 9 Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions","Azathioprine","34090-1 CLINICAL PHARMACOLOGY SECTION","TPMT","TPMT",,"Increased Toxicity Risk",,,"Take note that tests are avaliable",,,"Prodrug",,,,"MedicalCondition",,,
"urn:domeoclient:uuid:F880CCED-A2A0-4330-B02F-070F7BF5AF00","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf","WARNING: DEATH RELATED TO ULTRA-RAPID METABOLISM OF CODEINE TO MORPHINE\nRespiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism.","Codeine","34066-1 BOXED WARNING SECTION","CYP2D6","CYP2D6","Metabolism Increase","Increased Toxicity Risk",,,,,"ultra-metabolizer","Prodrug",,,,"MedicalCondition","ultra-metabolizer-positive",,"THIS ONE IS BROKEN, LOCATION OF ANNOTATION IS APPLIED TO IS INCORRECT."
"urn:domeoclient:uuid:F777C391-7D5E-4F49-948B-5B9ACB2587FA","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd","TPMT activity is controlled by a genetic polymorphism.1, 2, 3 For Caucasians and African Americans, approximately 10% of the population inherit one non-functional TPMT allele (heterozygous) conferring intermediate TPMT activity, and 0.3% inherit two TPMT non-functional alleles (homozygous) for low or absent TPMT activity. Non-functional alleles are less common in Asians. ","Azathioprine","34090-1 CLINICAL PHARMACOLOGY SECTION","TPMT","TPMT","Metabolism Decrease",,,,,,"low-or-absent-activity","Prodrug",,"Variant Frequency",,,,,
"urn:domeoclient:uuid:F5C240E5-0680-4CDA-ACC9-4DB8C5A0984B","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.","Abacavir","BOXED WARNING (34066-1)",,"HLA-B*5701",,,,,"Recommend",,"HLA-B*5701",,,,,"MedicalCondition","gene-haplotype-positive",,
"urn:domeoclient:uuid:F498E725-B59B-4357-806F-4F316B1EAB6C","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0","Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablet therapy.","Tamoxifen","34067-9 INDICATIONS AND USAGE SECTION","ESR1","ER_receptor",,"Increased Efficacy",,,,,,,,,,,,,
"urn:domeoclient:uuid:F19D3DA9-E091-415D-A43E-483BEC7B68FB","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02","Lipid Study: In a phase 3 safety trial in 262 post menopausal women with resected receptor positive early breast cancer at 24 months comparing the effects on lipid profiles of adjuvant letrozole to tamoxifen, 12% of patients on letrozole had at least one total cholesterol value of a higher CTCAE grade than at baseline compared with 4% of patients on tamoxifen.","Letrozole","34084-4 ADVERSE REACTIONS SECTION","ESR1, PGR","ER and PgR_receptor",,,,,,,,,,,"Clinical Trial","MedicalCondition","biomarker-positive",,
"urn:domeoclient:uuid:F10FC0DB-5D49-46E9-A2C2-3CFFC5FBF692","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b"," Patients carrying at least one copy of the CYP2C9*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele","Warfarin","66106-6 PHARMACOGENOMICS SECTION","CYP2C9","CYP2C9",,,,"Decrease from baseline",,,,,,,"Clinical Trial",,"gene-haplotype-positive","CYP2C9*2 ",
"urn:domeoclient:uuid:EED39F7C-032A-4628-9022-2253559E7FEE","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweighs the risk.","Abacavir","43685-7 WARNINGS AND PRECAUTIONS SECTION","HLA-B","HLA-B*5701",,,"Do not start",,,"Recommended",,,,,,,"gene-haplotype-positive","HLA-B*5701",
"urn:domeoclient:uuid:EE8AF84A-98F2-4EED-8B54-4312A50FBA31","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.","Abacavir","WARNINGS AND PRECAUTIONS (43685-7)",,"HLA-B*5701",,,,,"Recommend","Recommended","HLA-B*5701",,,,,,,,
"urn:domeoclient:uuid:EE521BAD-75B0-418A-A885-F72D473E4567","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b","VKORC1CYP2C9*Ranges are derived from multiple published clinical studies. Other clinical factors (e.g., age, race, body weight, sex, concomitant medications, and comorbidities) are generally accounted for along with genotype in the ranges expressed in the Table. VKORC11639 G(rs9923231) variant is used in this table. Other co-inherited VKORC1 variants may also be important determinants of warfarin dose. Patients with CYP2C9 *1/*3, *2/*2, *2/*3 and *3/*3 may require more prolonged time (>2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen.*1/*1*1/*2*1/*3*2/*2*2/*3*3/*3GG5 to 7 mg5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mgAG5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mgAA3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg","Warfarin","34068-7 DOSAGE AND ADMINISTRATION SECTION","UGT1A1","UGT1A1",,,,"Use specific",,,,,,,,,,,"FIX TABLE"
"urn:domeoclient:uuid:ED2F98CA-60F0-4D49-9803-FED968AA3114","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16bda7b5-a5a5-4478-9df3-beb396bd677f","Citalopram steady state levels were not significantly different in poor metabolizers and extensive metabolizers of CYP2D6.","Citalopram","43682-4 PHARMACOKINETICS SECTION","CYP2D6","CYP2D6","Not Important",,,,,,"poor-metabolizer",,,,,,"poor-metabolizer-positive",,
"urn:domeoclient:uuid:E7B4486A-24AB-4642-ADB0-B78FF5AF0E42","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf","\nRisk of death in ultra-rapid metabolizers: Conversion of codeine into its active metabolite, morphine, may occur more rapidly and completely resulting in higher than expected morphine levels and respiratory depression or death. ","Codeine","42229-5 SPL UNCLASSIFIED SECTION","CYP2D6",,"Metabolism Increase","Increased Toxicity Risk",,,,,"ultra-metabolizer","Prodrug",,,,"MedicalCondition","ultra-metabolizer-positive",,
"urn:domeoclient:uuid:E6578AA5-3295-46D7-B3F2-55CD3CFB5B0F","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb"," Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.","Abacavir","WARNINGS AND PRECAUTIONS (43685-7)",,"HLA-B*5701",,,"Do not restart",,,,"HLA-B*5701",,,,,"MedicalCondition",,,
"urn:domeoclient:uuid:E34142C5-1680-4612-AC76-D96D8F82364F","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Discontinue ZIAGEN as soon as a hypersensitivity reaction is suspected. Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.","Abacavir","42229-5 SPL UNCLASSIFIED SECTION","HLA-B","HLA-B*5701",,,"Discontinue/Do not restart",,,,,,,,,"MedicalCondition","gene-haplotype-positive","HLA-B*5701",
"urn:domeoclient:uuid:E1E45497-D882-456B-B573-7A640A307AFB","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1","Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is achieved through an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by genetic variations in CYP2C19 [see Boxed Warning] and by concomitant medications that interfere with CYP2C19.","Clopidogrel","43685-7 WARNINGS AND PRECAUTIONS SECTION","CYP2C19","CYP2C19","Metabolism Decrease","Decreased Efficacy",,,,,,"Prodrug","Concomitant medication concern",,,,,,
"urn:domeoclient:uuid:DF92C1E1-A223-4737-8028-06DD03B558D2","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.","Abacavir","WARNINGS AND PRECAUTIONS (43685-7)",,"HLA-B*5701",,,,,,,"HLA-B*5701",,,,,,,,
"urn:domeoclient:uuid:DEA4B73A-145A-4D61-A6E1-ABAE37F63480","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.","Abacavir","43685-7 WARNINGS AND PRECAUTIONS SECTION","HLA-B","HLA-B*5701",,,"Discontinue/Do not restart",,,,,,,,,"MedicalCondition","gene-haplotype-negative","HLA-B*5701",
"urn:domeoclient:uuid:DCF9A15D-3781-426E-B12E-C37A11772BAD","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1","Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy.","Clopidogrel","42229-5 SPL UNCLASSIFIED SECTION","CYP2C19","CYP2C19",,,,,"Take note that tests are avaliable",,,"Prodrug",,,,,,,
"urn:domeoclient:uuid:DBBF90A0-6468-4792-B1CC-02DDD21B4A08","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02","Bone Study: Results of a phase 3 safety trial in 262 post menopausal women with resected receptor positive early breast cancer in the adjuvant setting comparing the effect on lumbar spine (L2-L4) bone mineral density (BMD) of adjuvant treatment with letrozole to that with tamoxifen showed at 24 months a median decrease in lumbar spine BMD of 4.1% in the letrozole arm compared to a median increase of 0.3% in the tamoxifen arm (difference = 4.4%) (P<0.0001). No patients with a normal BMD at baseline became osteoporotic over the 2 years and only 1 patient with osteopenia at baseline (T score of -1.9) developed osteoporosis during the treatment period (assessment by central review). The results for total hip BMD were similar, although the differences between the two treatments were less pronounced. During the 2 year period, fractures were reported by 4 of 103 patients (4%) in the letrozole arm, and 6 of 97 patients (6%) in the tamoxifen arm.","Letrozole","34084-4 ADVERSE REACTIONS SECTION","ESR1, PGR",,,,,,,,,,,,"Clinical Trial",,"biomarker-positive",,
"urn:domeoclient:uuid:D640727D-6442-4274-B453-64F04BD595E3","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible","Abacavir","42229-5 SPL UNCLASSIFIED SECTION","HLA-B","HLA-B*5701",,,"Discontinue/Do not restart",,,,,,,,,"MedicalCondition","gene-haplotype-positive","HLA-B*5701",
"urn:domeoclient:uuid:D62A1217-AE83-41D2-B678-FDCD04344D8B","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","HLA-B*5701-negative patients may develop a hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.","Abacavir","WARNINGS AND PRECAUTIONS (43685-7)",,"HLA-B*5701",,,,,,,"HLA-B*5701",,,,,"MedicalCondition",,,
"urn:domeoclient:uuid:D5CF7A64-E07F-419A-8900-15F969F2D51F","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb"," Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.","Abacavir","WARNINGS AND PRECAUTIONS (43685-7)",,"HLA-B*5701",,,"Do not restart",,,,"HLA-B*5701",,,,,"MedicalCondition",,,
"urn:domeoclient:uuid:D3CF5A34-A1A9-4AFC-83F2-A5A1DD6DBB7F","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b","Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration. Not all patients with these conditions develop necrosis, and tissue necrosis occurs in patients without these deficiencies.","Warfarin","34071-1 WARNINGS SECTION","POLG",,,"Increased Toxicity Risk",,,,,,,,,,"MedicalCondition","biomarker-level-low",,"No gene symbol for protein S. Add a not there for the future.  Should we just remove this annotation"
"urn:domeoclient:uuid:D3B78E07-8B27-4774-B221-CC47DAC8365E","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.","Abacavir","BOXED WARNING (34066-1)",,"HLA-B*5701",,,,,,,"HLA-B*5701",,,,,"MedicalCondition",,,
"urn:domeoclient:uuid:D03D6753-24D2-4897-9947-4D727F406A9D","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=217e52b5-3a7b-4bbe-af3c-b18de7d426c3","Approximately 8% of Caucasians lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are extensive metabolizers (EM). PMs have about an 80% increase in aripiprazole exposure and about a 30% decrease in exposure to the active metabolite compared to EMs, resulting in about a 60% higher exposure to the total active moieties from a given dose of aripiprazole compared to EMs. Coadministration of ABILIFY with known inhibitors of CYP2D6, such as quinidine or fluoxetine in EMs, approximately doubles aripiprazole plasma exposure, and dose adjustment is needed [see DRUG INTERACTIONS (7.1)]. The mean elimination half-lives are about 75 hours and 146 hours for aripiprazole in EMs and PMs, respectively.","Aripiprazole","43682-4 PHARMACOKINETICS SECTION","CYP2D6","CYP2D6","Metabolism Decrease",,,,,,"poor-metabolizer",,"Concomitant medication concern","Variant Frequency",,,"poor-metabolizer-positive",,"We chose 1 annotation here.

How do we code for dose adjustment is needed? (does this mean time or a catch-all term)"
"urn:domeoclient:uuid:CF35511B-7BED-446A-B970-33FEE5C13C88","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0","One additional randomized study (NATO) demonstrated improved disease-free survival for tamoxifen compared to no adjuvant therapy following total mastectomy and axillary dissection in postmenopausal women with axillary node-negative breast cancer. In this study, the benefits of tamoxifen appeared to be independent of estrogen receptor status.","Tamoxifen","34092-7 CLINICAL STUDIES SECTION","ESR1","ER_receptor",,"Not Important",,,,,,,,,"Clinical Trial",,,,
"urn:domeoclient:uuid:CF0E7639-6AE6-4519-9A14-41BF8AB6A508","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16bda7b5-a5a5-4478-9df3-beb396bd677f","Citalopram steady state levels were not significantly different in poor metabolizers and extensive metabolizers of CYP2D6.","Citalopram","43682-4 PHARMACOKINETICS SECTION","CYP2D6","CYP2D6","Not Important",,,,,,"extensive-metabolizer",,,,,,,,
"urn:domeoclient:uuid:CE5D6919-6972-4689-B658-C5432A02F905","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.","Abacavir","BOXED WARNING (34066-1)",,"HLA-B*5701",,"Increased Toxicity Risk",,,,,"HLA-B*5701",,,,,"MedicalCondition",,,
"urn:domeoclient:uuid:CE4F247F-F7CB-4776-A379-05B0401FC08D","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b","VKORC1CYP2C9*Ranges are derived from multiple published clinical studies. Other clinical factors (e.g., age, race, body weight, sex, concomitant medications, and comorbidities) are generally accounted for along with genotype in the ranges expressed in the Table. VKORC11639 G(rs9923231) variant is used in this table. Other co-inherited VKORC1 variants may also be important determinants of warfarin dose. Patients with CYP2C9 *1/*3, *2/*2, *2/*3 and *3/*3 may require more prolonged time (>2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen.*1/*1*1/*2*1/*3*2/*2*2/*3*3/*3GG5 to 7 mg5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mgAG5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mgAA3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg","Warfarin","34068-7 DOSAGE AND ADMINISTRATION SECTION","CYP2C9",,,,,"Use specific",,,,,,,,,,,"FIX TABLE"
"urn:domeoclient:uuid:CE483709-CD8C-4493-A2B7-8E589B98BF31","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf","Advise patients that nursing mothers taking codeine can have higher morphine levels in their breast milk if they are ultra-rapid metabolizers. These higher levels of morphine in breast milk may lead to life-threatening or fatal side effects in nursing babies. Advise nursing mothers to watch for signs of morphine toxicity in their infants which includes increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness.","Codeine","42229-5 SPL UNCLASSIFIED SECTION","CYP2D6","CYP2D6","Metabolism Increase","Increased Toxicity Risk",,,,"Recommended","ultra-metabolizer","Prodrug",,,,"MedicalCondition","ultra-metabolizer-positive",,"PATIENT COUNSELING SECTION still not listed.  How do we code advise patients?"
"urn:domeoclient:uuid:CE3C3FF6-F83D-47D2-8C4F-944687265F2B","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Screening for carriage of the HLA -B*5701 allele is recommended prior to initiating treatment with abacavir. ","Abacavir","WARNINGS AND PRECAUTIONS (43685-7)",,"HLA-B*5701",,,,,"Recommend",,"HLA-B*5701",,,,,"MedicalCondition","gene-haplotype-positive",,
"urn:domeoclient:uuid:CE2D417D-24B3-4A7E-BE0B-FBF0E34B509B","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b"," The variant alleles CYP2C9*2 and CYP2C9*3 result in decreased in vitro CYP2C9 enzymatic 7-hydroxylation of S-warfarin. The frequencies of these alleles in Caucasians are approximately 11% and 7% for CYP2C9*2 and CYP2C9*3, respectively1. Patients with one or more of these variant CYP2C9 alleles have decreased S-warfarin clearance (Table 1).","Warfarin","43682-4 PHARMACOKINETICS SECTION","CYP2C9","CYP2C9","Metabolism Decrease",,,,,,,,,"Variant Frequency",,,"gene-haplotype-positive","CYP2C9*2, CYP2C9*3",
"urn:domeoclient:uuid:CE1DC1EA-085A-4CF9-8165-5A14A411A633","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","HLA-B*5701-negative patients may develop a hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.","Abacavir","43685-7 WARNINGS AND PRECAUTIONS SECTION","HLA-B","HLA-B*5701",,"Decreased Toxicity Risk",,,,,,,,,,"MedicalCondition","gene-haplotype-negative","HLA-B*5701",
"urn:domeoclient:uuid:CDE45635-21AB-4AC7-89FF-C772F3A15A2C","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1","Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers","Clopidogrel","34066-1 BOXED WARNING SECTION","CYP2C19","CYP2C19",,,"Alternative Recommended",,,,"poor-metabolizer","Prodrug",,,,,"poor-metabolizer-positive",,
"urn:domeoclient:uuid:CA5A93F5-5D2A-44BF-8951-9EF6DFE12F1B","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16bda7b5-a5a5-4478-9df3-beb396bd677f","The maximum dose should be limited to 20 mg/day in patients who are CYP2C19 poor metabolizers or those patients who may be taking concomitant cimetidine or another CYP2C19 inhibitor, since higher citalopram exposures would be expected.","Citalopram","WARNINGS (34071-1)","CYP2C19","CYP2C19","Excretion Decrease",,,"Decrease from baseline",,,"poor-metabolizer",,"Concomitant medication concern",,,,"poor-metabolizer-positive",,"Again, refers to increased exposure; we infer metabolism.  Said decrease from baseline as added a max dose."
"urn:domeoclient:uuid:CA417E62-D7D9-4F45-8359-10CCF8D13F90","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b","Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G>A allele) have been associated with lower dose requirements for warfarin. In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.5 Similar observations have been reported in Asian patients.","Warfarin","66106-6 PHARMACOGENOMICS SECTION","VKORC1","VKORC1",,,,"Decrease from baseline",,,,,,,"Clinical Trial",,"gene-SNP-positive","VKORC1-1639G>A",
"urn:domeoclient:uuid:C97CADE4-3861-4CB6-A21E-09BF0AEB1F88","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Based on this study, it is estimated that 61% of patients with the HLA-B*5701 allele will develop a clinically suspected hypersensitivity reaction during the course of abacavir treatment compared with 4% of patients who do not have the HLA-B*5701 allele.","Abacavir","WARNINGS AND PRECAUTIONS (43685-7)",,"HLA-B*5701",,,,,,,"HLA-B*5701",,,,,"MedicalCondition",,,
"urn:domeoclient:uuid:C89E80EC-0820-406B-99C8-D495EC5F054E","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf","WARNING: DEATH RELATED TO ULTRA-RAPID METABOLISM OF CODEINE TO MORPHINE\nRespiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism.","Codeine","42229-5 SPL UNCLASSIFIED SECTION","CYP2D6","CYP2D6","Metabolism Increase","Increased Toxicity Risk",,,,,"ultra-metabolizer","Prodrug",,,,"MedicalCondition","ultra-metabolizer-positive",,
"urn:domeoclient:uuid:C692DA9C-1ECF-4A5B-867C-ABAF23492F10","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1","A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metabolizer groups, evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg per day and 600 mg followed by 150 mg per day, each for a total of 5 days. Decreased active metabolite exposure and diminished inhibition of platelet aggregation were observed in the poor metabolizers as compared to the other groups. When poor metabolizers received the 600 mg/150 mg regimen, active metabolite exposure and antiplatelet response were greater than with the 300 mg/75 mg regimen (see Table 3). An appropriate dose regimen for this patient population has not been established in clinical outcome trials.","Clopidogrel","66106-6 PHARMACOGENOMICS SECTION","CYP2C19","CYP2C19","Metabolism Decrease","Decreased Efficacy",,,,,"poor-metabolizer","Prodrug",,,"Clinical Trial",,"poor-metabolizer-positive",,
"urn:domeoclient:uuid:C37B19E6-A2FE-4CF4-9914-61A4EF8E7827","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.","Abacavir","BOXED WARNING (34066-1)","HLA-B",,,"Decreased Toxicity Risk",,,,,,,,,,"MedicalCondition","gene-haplotype-negative","HLA-B*5701",
"urn:domeoclient:uuid:C24DFA02-2096-4634-974B-1866183BFD0B","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b","The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by:\n●\n     Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\n●\n     Genetic factors (CYP2C9 and VKORC1 genotypes).","Warfarin","34068-7 DOSAGE AND ADMINISTRATION SECTION","VKORC1","VKORC1",,"Influences Drug Response",,,,,,,,,,,,,
"urn:domeoclient:uuid:C1BF7FF6-707B-4750-BA47-274111148F96","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.","Abacavir","WARNINGS AND PRECAUTIONS (43685-7)",,"HLA-B*5701",,,"Do not restart",,,,"HLA-B*5701",,,,,"MedicalCondition",,,
"urn:domeoclient:uuid:C09E3379-98EF-4D6C-8046-8C000B4A6C99","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18","Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN. Consideration should be given to avoiding use of other drugs associated with SJS/TEN in HLA-B* 1502 positive patients, when alternative therapies are otherwise equally acceptable.","Carbamazepine","34071-1 WARNINGS SECTION","HLA-B","HLA-B*1502",,"Increased Toxicity Risk",,,,,,,"Concomitant medication concern",,,"MedicalCondition",,"HLA-B*1502 ","Drug selection refers to other drugs not drug of interest.  ?  Add Drug selection recommendation or not?"
"urn:domeoclient:uuid:BC0A4D53-4B45-488A-8775-B46BF1E9B010","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b"," Identification of risk factors for bleeding and certain genetic variations in CYP2C9 and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses ","Warfarin","42232-9 PRECAUTIONS SECTION","CYP2C9","CYP2C9",,,,"Decrease from baseline",,"Change monitoring strategy",,,,,,"MedicalCondition",,,
"urn:domeoclient:uuid:B8BA0ADB-2437-4F14-9102-2EC16B13EE4C","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02","Letrozole tablet is an aromatase inhibitor indicated for: \nAdjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer (1.1)\nExtended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy (1.2)\nFirst and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer","Letrozole","42229-5 SPL UNCLASSIFIED SECTION","ESR1, PGR","ER and PgR_receptor",,,,,,,,,,,,"MedicalCondition","biomarker-positive",,"Add drug selection recommendation of """indicated for""""
"urn:domeoclient:uuid:B752346E-6167-497D-B585-83983FA71DA2","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.","Abacavir","WARNINGS AND PRECAUTIONS (43685-7)",,"HLA-B*5701",,"Increased Toxicity Risk",,,,,"HLA-B*5701",,,,,,,,
"urn:domeoclient:uuid:B3811262-7FB7-4610-8AF2-DDBEC1F3F734","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.","Abacavir","34066-1 BOXED WARNING SECTION","HLA-B","HLA-B*5701",,,"Discontinue/Do not restart",,,,,,,,,"MedicalCondition","gene-haplotype-positive","HLA-B*5701 ",
"urn:domeoclient:uuid:B35B25D3-31CE-48B5-885E-844B46E97203","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Before starting ZIAGEN, tell your doctor about all of your medical conditions, including if you:\nhave been tested and know whether or not you have a particular gene variation called HLA-B*5701.","Abacavir","42231-1 SPL MEDGUIDE SECTION","HLA-B","HLA-B*5701",,,,,,,,,,,,,"gene-haplotype-negative","HLA-B*5701","how do we code \\\\\\\"""tell your doctor\\\\\\\""""
"urn:domeoclient:uuid:B2CCF84A-A981-4564-8227-DE5688CB1FED","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Patients taking ZIAGEN may have a serious allergic reaction (hypersensitivity reaction) that can cause death. Your risk of this allergic reaction is much higher if you have a gene variation called HLA-B*5701 than if you do not. Your doctor can determine with a blood test if you have this gene variation. ","Abacavir","PATIENT MEDICATION INFORMATION (68498-5)",,"HLA-B*5701",,,,,"Take note that tests are avaliable",,"HLA-B*5701",,,,,"MedicalCondition","gene-haplotype-positive",,
"urn:domeoclient:uuid:AE6AF907-607C-4B15-B108-FAD4D3010CA4","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweighs the risk.","Abacavir","43685-7 WARNINGS AND PRECAUTIONS SECTION","HLA-B","HLA-B*5701",,,"Discontinue/Do not restart",,,"Recommended",,,,,,,"gene-haplotype-positive","HLA-B*5701",
"urn:domeoclient:uuid:AC31138E-D96E-46FA-AD16-E8C5C6855989","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd","Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity from azathioprine tablets if conventional doses are given. Physicians may consider alternative therapies for patients who have low or absent TPMT activity (homozygous for non-functional alleles).","Azathioprine","34068-7 DOSAGE AND ADMINISTRATION SECTION","TPMT","TPMT",,"Increased Toxicity Risk","Alternative Recommended",,,,"low-or-absent-activity","Prodrug",,,,"MedicalCondition",,"homozygous for non-functional alleles","add to drop down; alleles necessary?"
"urn:domeoclient:uuid:AAB53C8F-FB14-4216-82D9-D7CD0AB15000","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1","Your doctor may do genetic tests to make sure clopidogrel tablets are right for you.","Clopidogrel","42231-1 SPL MEDGUIDE SECTION","CYP2C19","CYP2C19",,,,,"Take note that tests are avaliable",,,,,,,,,,
"urn:domeoclient:uuid:A753145C-8800-49A8-BE99-D558A1390DAE","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.","Abacavir","43685-7 WARNINGS AND PRECAUTIONS SECTION","HLA-B","HLA-B*5701",,,"Discontinue/Do not restart",,,,,,,,,"MedicalCondition","gene-haplotype-negative","HLA-B*5701",
"urn:domeoclient:uuid:A6AED276-0422-482B-8802-87BDABE2C035","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0","Benefit is less clear for women with ER poor breast cancer in whom the proportional reduction in recurrence was 10% (2p = 0.007) for all durations taken together, or 9% (2p = 0.02) if contralateral breast cancers are excluded. The corresponding reduction in mortality was 6% (NS).","Tamoxifen","34092-7 CLINICAL STUDIES SECTION","ESR1","ER_receptor",,,,,,,,,,,"Clinical Trial","MedicalCondition","biomarker-level-low",,
"urn:domeoclient:uuid:9F23E4DD-C825-4CCC-BD6E-1514188AFFA7","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16bda7b5-a5a5-4478-9df3-beb396bd677f","Citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation","Citalopram","43682-4 PHARMACOKINETICS SECTION","CYP2C19","CYP2C19",,"Increased Toxicity Risk",,"Decrease from baseline",,,"poor-metabolizer",,,,,"MedicalCondition","poor-metabolizer-positive",,
"urn:domeoclient:uuid:9EBC36A6-A85E-4348-8EBC-5B071D8A79FB","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1","Some published studies suggest that intermediate metabolizers have decreased active metabolite exposure and diminished antiplatelet effects.\\r\n\\r\nThe relationship between CYP2C19 genotype and clopidogrel bisulfate treatment outcome was evaluated in retrospective analyses of clopidogrel bisulfate-treated subjects in CHARISMA (n=2428) and TRITON-TIMI 38 (n=1477), and in several published cohort studies. In TRITON-TIMI 38 and the majority of the cohort studies, the combined group of patients with either intermediate or poor metabolizer status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolizers. In CHARISMA and one cohort study, the increased event rate was observed only in poor metabolizers.","Clopidogrel","66106-6 PHARMACOGENOMICS SECTION","CYP2C19","CYP2C19","Metabolism Decrease","Decreased Efficacy",,,,,"intermediate-metabolizer","Prodrug",,,"Clinical Trial","MedicalCondition",,,"add test result to drop down; check search of location using magnifying glass to make sure it comes up correct. It should be the same as the next one with and additional sentence for intermediate metabolizer."
"urn:domeoclient:uuid:9E9B14EC-233F-4ABE-B627-6150C0C5A5A4","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd","TPMT genotyping or phenotyping can help identify patients with low or absent TPMT activity (homozygous for non-functional alleles) who are at increased risk for severe, life-threatening myelosuppression from azathioprine tablets (see CLINICAL PHARMACOLOGY, WARNINGSand PRECAUTIONS: Laboratory Tests). Death associated with pancytopenia has been reported in patients with absent TPMT activity receiving azathioprine.","Azathioprine","34084-4 ADVERSE REACTIONS SECTION","TPMT","TPMT",,"Increased Toxicity Risk",,,"Take note that tests are avaliable",,"low-or-absent-activity","Prodrug",,,,"MedicalCondition",,,"add drop down choice to tests"
"urn:domeoclient:uuid:9E02315A-EB6D-4693-B3E4-4FB4B99D4253","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd","Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine.","Azathioprine","34071-1 WARNINGS SECTION","TPMT","TPMT",,"Increased Toxicity Risk",,,,,"low-or-absent-activity","Prodrug",,,,"MedicalCondition",,,"Add test result"
"urn:domeoclient:uuid:9E003EB3-2B97-41C7-BD14-5EAF744BB5F2","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd","The most common non-functional alleles associated with reduced levels of TPMT activity are TPMT*2, TPMT*3A and TPMT*3C. Patients with two non-functional alleles (homozygous) have low or absent TPMT activity and those with one non-functional allele (heterozygous) have intermediate activity.","Azathioprine","34075-2 LABORATORY TESTS SECTION","TPMT","TPMT","Metabolism Decrease",,,,,,"low-or-absent-activity","Prodrug",,"Variant Frequency",,,,"TPMT*2, TPMT*3A, TPMT*3C","include test results in dropdown"
"urn:domeoclient:uuid:9DDE5A30-59ED-49D7-B9B6-316245562477","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1","Poor metabolizers treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function.","Clopidogrel","42229-5 SPL UNCLASSIFIED SECTION","CYP2C19","CYP2C19",,"Decreased Efficacy",,,,,"poor-metabolizer","Prodrug",,,,"MedicalCondition","poor-metabolizer-positive",,
"urn:domeoclient:uuid:99AB6350-6929-4C24-B144-7B97EBF09B3F","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.","Abacavir","43685-7 WARNINGS AND PRECAUTIONS SECTION","HLA-B","HLA-B*5701",,"Increased Toxicity Risk",,,,,,,,,,"MedicalCondition","gene-haplotype-positive","HLA-B*5701 ",
"urn:domeoclient:uuid:9992ADBC-4BAB-4529-BAC4-9D7AFD34F098","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.","Abacavir","43685-7 WARNINGS AND PRECAUTIONS SECTION","HLA-B","HLA-B*5701",,,"Discontinue/Do not restart",,,,,,,,,"MedicalCondition","gene-haplotype-negative","HLA-B*5701",
"urn:domeoclient:uuid:98B929B0-EA85-44FF-B8CA-9D5AC804EBBB","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status","Abacavir","34070-3 CONTRAINDICATIONS SECTION","HLA-B","HLA-B*5701",,,"Discontinue/Do not restart",,,,,,,,,"MedicalCondition","gene-haplotype-positive","HLA-B*5701",
"urn:domeoclient:uuid:98743D23-3B02-4029-840D-D16A4F390F95","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Studies have shown that carriage of the HLA-B*5701 allele is associated with a significantly increased risk of a hypersensitivity reaction to abacavir.","Abacavir","43685-7 WARNINGS AND PRECAUTIONS SECTION","HLA-B","HLA-B*5701",,"Increased Toxicity Risk",,,,,,,,,,"MedicalCondition","gene-haplotype-positive","HLA-B*5701",
"urn:domeoclient:uuid:97CDCA51-103C-4EB7-BA80-9670B117D103","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0","Among women with ER positive or unknown breast cancer and positive nodes who received about 5 years of treatment, overall survival at 10 years was 61.4% for tamoxifen vs. 50.5% for control (logrank 2p < 0.00001). The recurrence-free rate at 10 years was 59.7% for tamoxifen vs. 44.5% for control (logrank 2p < 0.00001). Among women with ER positive or unknown breast cancer and negative nodes who received about 5 years of treatment, overall survival at 10 years was 78.9% for tamoxifen vs. 73.3% for control (logrank 2p < 0.00001). The recurrence-free rate at 10 years was 79.2% for tamoxifen vs. 64.3% for control (logrank 2p < 0.00001).","Tamoxifen","34092-7 CLINICAL STUDIES SECTION","ESR1","ER_receptor",,"Increased Efficacy",,,,,,,,,"Clinical Trial","MedicalCondition",,,
"urn:domeoclient:uuid:95EEC2FF-D292-48FE-8FD7-FEF64E2F00E4","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd","It is recommended that consideration be given to either genotype or phenotype patients for TPMT. Phenotyping and genotyping methods are commercially available.","Azathioprine","34075-2 LABORATORY TESTS SECTION","TPMT","TPMT",,,,,"Recommend",,,"Prodrug",,,,,,,
"urn:domeoclient:uuid:942AE26F-116C-4165-9118-723E840DFB17","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1","Tests are available to determine a patient’s CYP2C19 genotype.","Clopidogrel","66106-6 PHARMACOGENOMICS SECTION","CYP2C19","CYP2C19",,,,,"Take note that tests are avaliable",,,"Prodrug",,,,,,,
"urn:domeoclient:uuid:91050818-2692-4B82-B3D8-A52A364F00D7","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf","Advise patients that some people have a genetic variation that results in codeine changing into morphine more rapidly and completely than other people. Most people are unaware of whether they are an ultra-rapid codeine metabolizer or not. These higher-than-normal levels of morphine in the blood may lead to life-threatening or fatal respiratory depression or signs of overdose such as extreme sleepiness, confusion, or shallow breathing. Children with this genetic variation who were prescribed codeine after tonsillectomy and/or adenoidectomy for obstructive sleep apnea may be at greatest risk based on reports of several deaths in this population due to respiratory depression.","Codeine","42229-5 SPL UNCLASSIFIED SECTION","CYP2D6","CYP2D6","Metabolism Increase","Increased Toxicity Risk",,,,,"ultra-metabolizer","Prodrug",,,,"MedicalCondition","ultra-metabolizer-positive",,"PATIENT COUNSELING SECTION still not listed.  How do we code advise patients?"
"urn:domeoclient:uuid:90E4AF52-01F4-4371-B3ED-D400FF8B1C1E","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0"," In a small substudy (N = 81) of the NSABP P-1 trial, there appeared to be no benefit to screening women for Factor V Leiden and Prothrombin mutations G20210A as a means to identify those who may not be appropriate candidates for tamoxifen therapy.","Tamoxifen","34071-1 WARNINGS SECTION","F2",,,,,,"Not necessary",,,,,,,,,,
"urn:domeoclient:uuid:90768224-544A-41CF-9969-E08884F1434D","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1","The relationship between CYP2C19 genotype and clopidogrel bisulfate treatment outcome was evaluated in retrospective analyses of clopidogrel bisulfate-treated subjects in CHARISMA (n=2428) and TRITON-TIMI 38 (n=1477), and in several published cohort studies. In TRITON-TIMI 38 and the majority of the cohort studies, the combined group of patients with either intermediate or poor metabolizer status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolizers. In CHARISMA and one cohort study, the increased event rate was observed only in poor metabolizers.","Clopidogrel","66106-6 PHARMACOGENOMICS SECTION","CYP2C19","CYP2C19","Metabolism Decrease","Decreased Efficacy",,,,,"poor-metabolizer","Prodrug",,,"Clinical Trial","MedicalCondition","poor-metabolizer-positive",,
"urn:domeoclient:uuid:8F4ED235-6F4A-4BDD-A23F-6F2D9FC7A396","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf"," In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine’s active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants.","Codeine","34080-2 NURSING MOTHERS SECTION","CYP2D6","CYP2D6","Metabolism Increase","Increased Toxicity Risk",,,,,"ultra-metabolizer","Prodrug",,,,"MedicalCondition","ultra-metabolizer-positive",,"Did not annotate normal separately in this case."
"urn:domeoclient:uuid:8D91E7D5-B379-4649-9834-0D01A948DFF8","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf","Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience signs of overdose (such as extreme sleepiness, confusion, or shallow breathing)","Codeine","43685-7 WARNINGS AND PRECAUTIONS SECTION","CYP2D6","CYP2D6",,"Increased Toxicity Risk",,,,,"ultra-metabolizer","Prodrug",,,,"MedicalCondition","ultra-metabolizer-positive",,
"urn:domeoclient:uuid:8CD7F86F-C041-47B7-B7D2-F7B48F523F56","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.","Abacavir","42229-5 SPL UNCLASSIFIED SECTION","HLA-B","HLA-B*5701",,"Increased Toxicity Risk",,,,,,,,,,"MedicalCondition","gene-haplotype-positive","HLA-B*5701",
"urn:domeoclient:uuid:8B50CE5B-C2BB-4D97-838E-E1C2600020BC","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb"," Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.","Abacavir","WARNINGS AND PRECAUTIONS (43685-7)",,"HLA-B*5701",,,"Do not restart",,,,"HLA-B*5701",,,,,,,,
"urn:domeoclient:uuid:8B4BE2A8-5AB2-47D3-A46D-2D1D5E7AC42F","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0","NSABP B-14, a prospective, double-blind, randomized study, compared tamoxifen to placebo in women with axillary node-negative, estrogen receptor positive (≥ 10 fmol/mg cytosol protein) breast cancer (as adjuvant therapy, following total mastectomy and axillary dissection, or segmental resection, axillary dissection, and breast radiation). After 5 years of treatment, there was a significant improvement in disease-free survival in women receiving tamoxifen. This benefit was apparent both in women under age 50 and in women at or beyond age 50.","Tamoxifen","34092-7 CLINICAL STUDIES SECTION","ESR1","ER_receptor",,"Increased Efficacy",,,,,,,,,"Clinical Trial","MedicalCondition","biomarker-positive",,"mixing terminology... positive and high/low for biomarker test results"
"urn:domeoclient:uuid:8B036858-70F5-4077-8333-F34F19A042EC","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf","Nursing mothers who are ultra-rapid metabolizers may also experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding","Codeine","34080-2 NURSING MOTHERS SECTION","CYP2D6","CYP2D6",,"Increased Toxicity Risk",,,,"Recommended","ultra-metabolizer","Prodrug",,,,"MedicalCondition","ultra-metabolizer-positive",,
"urn:domeoclient:uuid:89320F5F-262D-4657-8A52-4432EC0101F8","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweighs the risk.","Abacavir","WARNINGS AND PRECAUTIONS (43685-7)",,"HLA-B*5701",,,"Do not restart",,,"Recommended","HLA-B*5701",,,,,"MedicalCondition",,,
"urn:domeoclient:uuid:88C2CEB5-469C-451E-8436-788ABE4338F5","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd","TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE TABLETS. TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity.","Azathioprine","34068-7 DOSAGE AND ADMINISTRATION SECTION","TPMT","TPMT",,,,,"Take note that tests are avaliable","Required","low-or-absent-activity","Prodrug",,,,,,,
"urn:domeoclient:uuid:86565D69-8F9C-4519-9A52-CD2A2980DEE3","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0","The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) conducted worldwide overviews of systemic adjuvant therapy for early breast cancer in 1985, 1990, and again in 1995. In 1998, 10 year outcome data were reported for 36,689 women in 55 randomized trials of adjuvant tamoxifen using doses of 20 to 40 mg/day for 1 to 5+ years. Twenty-five percent of patients received one year or less of trial treatment, 52% received 2 years, and 23% received about 5 years. Forty-eight percent of tumors were estrogen receptor (ER) positive (> 10 fmol/mg), 21% were ER poor (< 10 fmol/l), and 31% were ER unknown. Among 29,441 patients with ER positive or unknown breast cancer, 58% were entered into trials comparing tamoxifen to no adjuvant therapy and 42% were entered into trials comparing tamoxifen in combination with chemotherapy vs. the same chemotherapy alone.","Tamoxifen","34092-7 CLINICAL STUDIES SECTION","ESR1","ER_receptor",,,,,,,,,,"Variant Frequency","Clinical Trial","MedicalCondition","biomarker-positive",,
"urn:domeoclient:uuid:86218E9C-9C50-4CF1-BDF5-7480485335DE","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb"," If the patient is of unknown HLA-B*5701 status, screening for the allele is recommended prior to reinitiation of ZIAGEN.","Abacavir","WARNINGS AND PRECAUTIONS (43685-7)",,"HLA-B*5701",,,,,"Recommend",,"HLA-B*5701",,,,,"MedicalCondition","gene-haplotype-positive",,
"urn:domeoclient:uuid:8525CDF6-1EFA-4AA5-BD43-C9DDE92E0196","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02","Letrozole tablets was initially studied at doses of 0.1 mg to 5.0 mg daily in six non-comparative Phase I/II trials in 181 postmenopausal estrogen/progesterone receptor positive or unknown advanced breast cancer patients previously treated with at least antiestrogen therapy. Patients had received other hormonal therapies and also may have received cytotoxic therapy. Eight (20%) of forty patients treated with letrozole tablets 2.5 mg daily in Phase I/II trials achieved an objective tumor response (complete or partial response).","Letrozole","34092-7 CLINICAL STUDIES SECTION","ESR1, PGR","ER and PgR_receptor",,,,,,,,,,,"Clinical Trial","MedicalCondition","biomarker-positive",,
"urn:domeoclient:uuid:83E53A9A-8702-4167-A12D-1370E2D26E06","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.","Abacavir","34066-1 BOXED WARNING SECTION","HLA-B","HLA-B*5701",,,,,"Recommend",,,,,,,"MedicalCondition",,"HLA-B*5701",
"urn:domeoclient:uuid:7FDE7EC5-68D1-4D11-A164-0B2DA9D73292","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b","Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient's VKORC1 genotype. ","Warfarin","43679-0 MECHANISM OF ACTION SECTION","VKORC1","VKORC1",,"Influences Drug Response",,,,,,,,,,,,,
"urn:domeoclient:uuid:7FA5409D-3EA5-4F92-B738-8577DCEB4D97","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","If the patient is of unknown HLA-B*5701 status, screening for the allele is recommended prior to reinitiation of ZIAGEN.","Abacavir","43685-7 WARNINGS AND PRECAUTIONS SECTION","HLA-B","HLA-B*5701",,,,,"Recommend",,,,,,,,,"HLA-B*5701",
"urn:domeoclient:uuid:7D8A9803-9C09-4301-8254-AF8BCE7E83F8","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b","The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose. Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose.","Warfarin","34068-7 DOSAGE AND ADMINISTRATION SECTION","CYP2C9","CYP2C9",,,,"Use specific",,,,,,,,,,,
"urn:domeoclient:uuid:7D37999E-F183-41DD-8FEF-19696FD23D30","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1","Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy","Clopidogrel","34066-1 BOXED WARNING SECTION","CYP2C19","CYP2C19",,,,,"Take note that tests are avaliable",,,"Prodrug",,,,,,,
"urn:domeoclient:uuid:7B209F2D-47BE-4267-B895-92D67A47AE61","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf","Respiratory depression and death have occurred in children who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 [CYP2D6] or high morphine concentrations)","Codeine","43685-7 WARNINGS AND PRECAUTIONS SECTION","CYP2D6","CYP2D6",,"Increased Toxicity Risk",,,,,"ultra-metabolizer","Prodrug",,,,"MedicalCondition","ultra-metabolizer-positive","multiple copies of the gene for cytochrome P450 isoenzyme 2D6 [CYP2D6] ","multiple copies of gene in allele section?"
"urn:domeoclient:uuid:79AEDAF0-0AC0-4A44-9F6D-05B14ECEF74F","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Screening for carriage of the HLA -B*5701 allele is recommended prior to initiating treatment with abacavir. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.","Abacavir","43685-7 WARNINGS AND PRECAUTIONS SECTION","HLA-B","HLA-B*5701",,,,,"Recommend",,,,,,,,,"HLA-B*5701",
"urn:domeoclient:uuid:75A79304-2BD1-4F33-9391-4BB93929D4E6","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b","The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by:\n●\n     Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\n●\n     Genetic factors (CYP2C9 and VKORC1 genotypes).","Warfarin","34068-7 DOSAGE AND ADMINISTRATION SECTION","CYP2C9","CYP2C9",,"Influences Drug Response",,,,,,,,,,,,,
"urn:domeoclient:uuid:74791FAB-E4B4-4EA3-9557-BD68EDB49B01","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b","CYP2C9 GenotypeNS-Warfarin Clearance/Lean Body Weight(mL/min/kg)Mean (SD)**SD=standard deviation.p<0.001. Pairwise comparisons indicated significant differences among all 3 genotypes.*1/*11180.065 (0.025)*1/*2 or*1/*3590.041 (0.021)*2/*2, *2/*3or *3/*3110.020 (0.011)Total188Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including *5, *6, and *11 alleles in populations of African ancestry and *5, *9 and *11 alleles in Caucasians.","Warfarin","43682-4 PHARMACOKINETICS SECTION","CYP2C9","CYP2C9","Metabolism Decrease",,,,,,,,,"Variant Frequency",,,"gene-haplotype-positive","CYP2C9*1/*1, CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, CYP2C9*2/*3, CYP2C9*3/*3, CYP2C9*5, CYP2C9*6, CYP2C9*11, CYP2C9*9",
"urn:domeoclient:uuid:720C5233-AF5F-4538-891A-259FD3EE6895","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02","Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.","Letrozole","34067-9 INDICATIONS AND USAGE SECTION","ESR1, PGR","ER and PgR_receptor",,,,,,,,,,,,"MedicalCondition","biomarker-positive",,"Add drug selection recommendation of """indicated for""""
"urn:domeoclient:uuid:7084C584-8C84-42A3-AFAB-F66F243A2817","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b","A meta-analysis of 9 qualified studies including 2775 patients (99% Caucasian) was performed to examine the clinical outcomes associated with CYP2C9 gene variants in warfarin-treated patients.3 In this meta-analysis, 3 studies assessed bleeding risks and 8 studies assessed daily dose requirements. The analysis suggested an increased bleeding risk for patients carrying either the CYP2C9*2 or CYP2C9*3 alleles.","Warfarin","66106-6 PHARMACOGENOMICS SECTION","CYP2C9","CYP2C9",,"Increased Toxicity Risk",,,,,,,,,"Clinical Trial","MedicalCondition",,"CYP2C9*2, CYP2C9*3",
"urn:domeoclient:uuid:6E1788A3-66E3-4952-B193-2C5E9B1AB551","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b"," Numerous factors, alone or in combination, including changes in diet, medications, botanicals and genetic variations in the CYP2C9 and VKORC1 enzymes (seeCLINICAL PHARMACOLOGY,Pharmacogenomics) may influence the response of the patient to warfarin.","Warfarin","42232-9 PRECAUTIONS SECTION","CYP2C9","CYP2C9",,"Influences Drug Response",,,,,,,,,,,,,
"urn:domeoclient:uuid:6D4DAD4D-1B63-4482-8060-787D97F917D2","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd","Patients receiving azathioprine tablets and allopurinol concomitantly should have a dose reduction of azathioprine tablets, to approximately ⅓ to ¼ the usual dose. It is recommended that a further dose reduction or alternative therapies be considered for patients with low or absent TPMT activity receiving azathioprine tablets and allopurinol because both TPMT and XO inactivation pathways are affected","Azathioprine","34073-7 DRUG INTERACTIONS SECTION","TPMT","TPMT","Metabolism Decrease",,"Alternative Recommended","Decrease from baseline",,,"low-or-absent-activity","Prodrug","Concomitant medication concern",,,,,,"Add test result to drop down"
"urn:domeoclient:uuid:6A2E1BD4-3863-4A37-AD9D-6B54F3CF3E54","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf","Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype (gene duplications denoted as *1/*1xN or *1/*2xN). The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. ","Codeine","43685-7 WARNINGS AND PRECAUTIONS SECTION","CYP2D6","CYP2D6","Metabolism Increase",,,,,,"ultra-metabolizer","Prodrug",,"Variant Frequency",,,"ultra-metabolizer-positive","CYP2D6*1/*1xN, CYP2D6*1/*2xN",
"urn:domeoclient:uuid:69B50E0E-4BB4-49DC-AE8B-4326D0F0A959","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0","An anastrozole adjuvant trial was conducted in 9,366 postmenopausal women with operable breast cancer who were randomized to receive adjuvant treatment with either anastrozole 1 mg daily, tamoxifen 20 mg daily, or a combination of these two treatments for 5 years or until recurrence of the disease. At a median follow-up of 33 months, the combination of anastrozole and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen therapy alone in all patients as well as in the hormone receptor positive subpopulation. This treatment arm was discontinued from the trial.","Tamoxifen","34092-7 CLINICAL STUDIES SECTION","ESR1","ER_receptor",,"Not Important",,,,,,,,,"Clinical Trial","MedicalCondition","biomarker-positive",,
"urn:domeoclient:uuid:671F2493-9F0B-4BB9-94E6-4B432F418763","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18","For genetically at-risk patients [See WARNINGS], high-resolution 'HLA-B*1502 typing' is recommended. The test is positive if either one or two HLA-B*1502 alleles are detected and negative if no HLA-B*1502 alleles are detected.","Carbamazepine","34075-2 LABORATORY TESTS SECTION","HLA-B","HLA-B*1502",,,,,"Recommend",,,,,,,,,"HLA-B*1502",
"urn:domeoclient:uuid:65BD7CC9-2CFA-43C3-A5F0-FBC0221449BF","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1","The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional.","Clopidogrel","66106-6 PHARMACOGENOMICS SECTION","CYP2C19","CYP2C19",,,,,,,"extensive-metabolizer","Prodrug",,,,,,"CYP2C19*1 ",
"urn:domeoclient:uuid:60281E0C-D291-4163-9B6F-E83A4142CB8E","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd","Patients with intermediate TPMT activity may be at increased risk of myelotoxicity if receiving conventional doses of azathioprine tablets.","Azathioprine","34090-1 CLINICAL PHARMACOLOGY SECTION","TPMT","TPMT",,"Increased Toxicity Risk",,,,,"intermediate-activity","Prodrug",,,,"MedicalCondition",,,"Add test result"
"urn:domeoclient:uuid:5EE59E00-2977-4F09-A933-867C3E165210","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b","Identification of risk factors for bleeding and certain genetic variations in CYP2C9 and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses ","Warfarin","42232-9 PRECAUTIONS SECTION","VKORC1","VKORC1",,,,"Decrease from baseline",,"Change monitoring strategy",,,,,,"MedicalCondition",,,
"urn:domeoclient:uuid:5D7649B4-7723-40DE-B9AD-4926156D8C0A","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18","Retrospective case-control studies have found that in patients of Chinese ancestry there is a strong association between the risk of developing SJS/TEN with carbamazepine treatment and the presence of an inherited variant of the HLA-B gene, HLA-B*1502. The occurrence of higher rates of these reactions in countries with higher frequencies of this allele suggests that the risk may be increased in allele-positive individuals of any ethnicity.\nAcross Asian populations, notable variation exists in the prevalence of HLA-B*1502. Greater than 15% of the population is reported positive in Hong Kong, Thailand, Malaysia, and parts of the Philippines, compared to about 10% in Taiwan and 4% in North China. South Asians, including Indians, appear to have intermediate prevalence of HLA-B*1502, averaging 2 to 4%, but higher in some groups. HLA-B*1502 is present in <1% of the population in Japan and Korea.\nHLA-B*1502 is largely absent in individuals not of Asian origin (e.g., Caucasians, African-Americans, Hispanics, and Native Americans)","Carbamazepine","34071-1 WARNINGS SECTION","HLA-B","HLA-B*1502",,,,,,,,,,"Variant Frequency","Clinical Trial","MedicalCondition",,"HLA-B*1502",
"urn:domeoclient:uuid:5CCA20AA-4D3C-40F4-BAED-C832E665FA35","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1","The effectiveness of clopidogrel bisulfate is dependent on its activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 [see Warnings and Precautions (5.1)]. Clopidogrel bisulfate at recommended doses forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers","Clopidogrel","34066-1 BOXED WARNING SECTION","CYP2C19","CYP2C19","Metabolism Decrease","Decreased Efficacy",,,,,"poor-metabolizer","Prodrug",,,,,"poor-metabolizer-positive",,
"urn:domeoclient:uuid:5B7239DA-6BB5-450F-B107-37E66914C66D","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0","In the Hubay study, patients with a positive (more than 3 fmol) estrogen receptor were more likely to benefit.","Tamoxifen","34092-7 CLINICAL STUDIES SECTION","ESR1","ER_receptor",,"Increased Efficacy",,,,,,,,,"Clinical Trial",,"biomarker-positive",,
"urn:domeoclient:uuid:59E6E4F8-DCB3-4875-86B2-D5885FD80EF7","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18","PATIENTS TESTING POSITIVE FOR THE ALLELE SHOULD NOT BE TREATED WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES UNLESS THE BENEFIT CLEARLY OUTWEIGHS THE RISK","Carbamazepine","34066-1 BOXED WARNING SECTION","HLA-B","HLA-B*1502",,,"Do not start",,,,,,,,,,"gene-haplotype-positive",,
"urn:domeoclient:uuid:5949C0ED-ECE8-4C36-B91D-8E58F7A36AAC","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Risk Factor: HLA-B*5701 Allele: Studies have shown that carriage of the HLA-B*5701 allele is associated with a significantly increased risk of a hypersensitivity reaction to abacavir.","Abacavir","CLINICAL STUDIES (34092-7)",,"HLA-B*5701",,"Increased Toxicity Risk",,,,,"HLA-B*5701",,,,,,,,
"urn:domeoclient:uuid:58D07047-AF21-4623-8E4E-4CB2945F5986","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02","Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents). These interventions lead to decreased tumor mass or delayed progression of tumor growth in some women.","Letrozole","43679-0 MECHANISM OF ACTION SECTION","ESR1, PGR","ER and PgR_receptor",,,,,,,,,,,,"MedicalCondition","biomarker-positive",,"Add drug selection recommendation of """indicated for""""
"urn:domeoclient:uuid:56ECCD1C-D5DA-4A5F-A470-A96F404E1CB8","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0"," Tamoxifen decreased the incidence of small estrogen receptor positive tumors, but did not alter the incidence of estrogen receptor negative tumors or larger tumors.","Tamoxifen","42232-9 PRECAUTIONS SECTION","ESR1","ER_receptor",,"Increased Efficacy",,,,,,,,,,,"biomarker-positive",,
"urn:domeoclient:uuid:5630014D-C820-4E31-A061-529A1A06548B","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.","Abacavir","WARNINGS AND PRECAUTIONS (43685-7)",,"HLA-B*5701",,,,,"Recommend",,"HLA-B*5701",,,,,"MedicalCondition","gene-haplotype-positive",,
"urn:domeoclient:uuid:55ED86AA-B414-4220-94FD-868AFE2D1278","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b"," For patients carrying at least one copy of the CYP2C9*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele.","Warfarin","66106-6 PHARMACOGENOMICS SECTION","CYP2C9","CYP2C9",,,,"Decrease from baseline",,,,,,,"Clinical Trial",,"gene-haplotype-positive","CYP2C9*3",
"urn:domeoclient:uuid:55700EE9-88B8-49B7-BD64-1A87D99DCC15","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b"," In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.5 Similar observations have been reported in Asian patients.","Warfarin","66106-6 PHARMACOGENOMICS SECTION","CYP2C9",,,,,,,,,,,,"Clinical Trial",,,,"Did not say provided specific dose recommendations."
"urn:domeoclient:uuid:5464F1B8-CF3D-4DA9-99F4-5F156C14CE70","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.","Abacavir","WARNINGS AND PRECAUTIONS (43685-7)",,"HLA-B*5701",,,,,"Recommend",,"HLA-B*5701",,,,,"MedicalCondition","gene-haplotype-positive",,
"urn:domeoclient:uuid:524C3AB2-2955-4538-A46C-63CDD0BC11D2","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.","Abacavir","BOXED WARNING (34066-1)",,"HLA-B*5701",,,"Do not restart",,,,"HLA-B*5701",,,,,,,,"Need an option for discontinue"
"urn:domeoclient:uuid:5229A912-1F9A-40AD-9994-79886D701F6C","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0","In a small substudy (N = 81) of the NSABP P-1 trial, there appeared to be no benefit to screening women for Factor V Leiden and Prothrombin mutations G20210A as a means to identify those who may not be appropriate candidates for tamoxifen therapy.","Tamoxifen","34071-1 WARNINGS SECTION","F5",,,,,,"Not necessary",,,,,,,,,,
"urn:domeoclient:uuid:51CDF79D-8F09-44DB-AE3B-91C93D13095C","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb"," Patients taking ZIAGEN may have a serious allergic reaction (hypersensitivity reaction) that can cause death. Your risk of this allergic reaction is much higher if you have a gene variation called HLA-B*5701 than if you do not. ","Abacavir","PATIENT MEDICATION INFORMATION (68498-5)",,"HLA-B*5701",,,,,,,"HLA-B*5701",,,,,"MedicalCondition",,,
"urn:domeoclient:uuid:4F5C1D0C-9AFC-4B3A-83EC-AC9CB72FB0C9","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf","Deaths have also occurred in nursing infants who were exposed to high levels of morphine in breast milk because their mothers were ultra-rapid metabolizers of codeine ","Codeine","43685-7 WARNINGS AND PRECAUTIONS SECTION","CYP2D6","CYP2D6","Metabolism Increase","Increased Toxicity Risk",,,,,"ultra-metabolizer","Prodrug",,,,"MedicalCondition","ultra-metabolizer-positive",,
"urn:domeoclient:uuid:4BED623F-9685-4D95-8EAD-FDE3617D193B","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0","Tamoxifen citrate tablets are a prescription medicine that is like estrogen (female hormone) in some ways and different in other ways. In the breast, tamoxifen can block estrogen's effects. Because it does this, tamoxifen may block the growth of breast cancers that need estrogen to grow (cancers that are estrogen- or progesterone-receptor positive).","Tamoxifen","42231-1 SPL MEDGUIDE SECTION","ESR1, PGR","ER and PgR_receptor",,"Influences Drug Response",,,,,,,,,,"MedicalCondition",,,
"urn:domeoclient:uuid:47718F61-F7FA-4A83-BB17-C13189D5E884","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir. ","Abacavir","BOXED WARNING (34066-1)",,"HLA-B*5701",,,,,,,"HLA-B*5701",,,,,"MedicalCondition",,,
"urn:domeoclient:uuid:46C63D3B-0000-404E-BC76-FB01C42DC7B2","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18","STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE. HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES.","Carbamazepine","34066-1 BOXED WARNING SECTION","HLA-B","HLA-B*1502",,"Increased Toxicity Risk",,,"Recommend",,,,,"Variant Frequency",,"MedicalCondition",,"HLA-B*1502",
"urn:domeoclient:uuid:44BBF444-A1D4-4182-8B05-775BFFCA0DF4","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1","Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers.","Clopidogrel","42229-5 SPL UNCLASSIFIED SECTION","CYP2C19","CYP2C19",,,"Alternative Recommended",,,,"poor-metabolizer","Prodrug",,,,,"poor-metabolizer-positive",,
"urn:domeoclient:uuid:43CE071E-85A3-4BC0-AEAC-4FC4DCBB3D02","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0","The effect of the scheduled duration of tamoxifen may be described as follows. In women with ER positive or unknown breast cancer receiving 1 year or less, 2 years or about 5 years of tamoxifen, the proportional reductions in mortality were 12%, 17% and 26%, respectively (trend significant at 2p < 0.003). The corresponding reductions in breast cancer recurrence were 21%, 29% and 47% (trend significant at 2p < 0.00001).","Tamoxifen","34092-7 CLINICAL STUDIES SECTION","ESR1","ER_receptor",,"Increased Efficacy",,,,,,,,,"Clinical Trial","MedicalCondition","poor-metabolizer-positive",,"how to annotation increased effect with increased duration of therapy (PD?)"
"urn:domeoclient:uuid:4364906C-8414-403A-BB1D-1DDCC5F6A4DA","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb"," NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status","Abacavir","CONTRAINDICATIONS (34070-3)",,"HLA-B*5701",,,"Do not restart",,,,"HLA-B*5701",,,,,"MedicalCondition",,,
"urn:domeoclient:uuid:420A3DFE-8247-4E9B-8E6C-368F1A2C415C","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.","Abacavir","43685-7 WARNINGS AND PRECAUTIONS SECTION","HLA-B","HLA-B*5701",,,"Do not start",,,"Recommended",,,,,,,"gene-haplotype-positive","HLA-B*5701",
"urn:domeoclient:uuid:41CC62A5-5C3A-449F-B7A3-675F76FA4085","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16bda7b5-a5a5-4478-9df3-beb396bd677f","20 mg/day is the maximum recommended dose for patients who are greater than 60 years of age, patients with hepatic impairment, and for CYP2C19 poor metabolizers or those patients taking cimetidine or another CYP2C19 inhibitor","Citalopram","DOSAGE AND ADMINISTRATION (34068-7)","CYP2C19","CYP2C19",,,,"Decrease from baseline",,,"poor-metabolizer",,"Concomitant medication concern",,,,,,
"urn:domeoclient:uuid:40B2A403-27A7-43FE-A0AC-5D87E3545981","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b","Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration. Not all patients with these conditions develop necrosis, and tissue necrosis occurs in patients without these deficiencies.","Warfarin","34071-1 WARNINGS SECTION","POLG",,,"Increased Toxicity Risk",,,,,,,,,,"MedicalCondition","biomarker-level-low",,"No gene symbol for protein C (PROC) and protein S.  Add a not there for the future."
"urn:domeoclient:uuid:408C86B9-FFBA-4A7F-A6EC-ECD348FD4782","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1","CYP2C19 poor metabolizer status is associated with diminished antiplatelet response to clopidogrel. Although a higher dose regimen in poor metabolizers increases antiplatelet response [see Clinical Pharmacology (12.5)], an appropriate dose regimen for this patient population has not been established.","Clopidogrel","34068-7 DOSAGE AND ADMINISTRATION SECTION","CYP2C19","CYP2C19",,"Decreased Efficacy",,,,,"poor-metabolizer","Prodrug",,,,,"poor-metabolizer-positive",,
"urn:domeoclient:uuid:405A5AAA-08FD-470C-9B50-67E44ED1462F","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd","Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine tablets.","Azathioprine","34090-1 CLINICAL PHARMACOLOGY SECTION","TPMT","TPMT",,"Increased Toxicity Risk",,,,,"low-or-absent-activity","Prodrug",,,,"MedicalCondition",,,"Added test results (or categorize as poor?)"
"urn:domeoclient:uuid:3D5D3473-95BD-41AF-81E6-ED19E81798E9","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Discontinue ZIAGEN as soon as a hypersensitivity reaction is suspected. Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.","Abacavir","42229-5 SPL UNCLASSIFIED SECTION","HLA-B","HLA-B*5701",,,"Discontinue/Do not restart",,,,,,,,,"MedicalCondition","gene-haplotype-negative","HLA-B*5701",
"urn:domeoclient:uuid:3D5B3334-40F5-4B23-8773-AFED2978DC1D","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b"," Numerous factors, alone or in combination, including changes in diet, medications, botanicals and genetic variations in the CYP2C9 and VKORC1 enzymes (seeCLINICAL PHARMACOLOGY,Pharmacogenomics) may influence the response of the patient to warfarin.","Warfarin","42232-9 PRECAUTIONS SECTION","VKORC1","VKORC1",,"Influences Drug Response",,,,,,,,,,,,,
"urn:domeoclient:uuid:3CB531B1-A267-4A03-A0C5-D852AB638802","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd","TPMT genotyping or phenotyping can help identify patients who are at an increased risk for developing azathioprine toxicity.","Azathioprine","34075-2 LABORATORY TESTS SECTION","TPMT","TPMT",,"Increased Toxicity Risk",,,"Take note that tests are avaliable",,,"Prodrug",,,,"MedicalCondition",,,
"urn:domeoclient:uuid:3C852929-ADD4-4383-A351-2D9CF492A6E9","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18","If you are of Asian descent you may need a genetic blood test before you take Carbamazepine Extended-Release Capsules to see if you are at a higher risk for serious skin reactions with this medicine.","Carbamazepine","42231-1 SPL MEDGUIDE SECTION","HLA-B","HLA-B*1502",,,,,"Take note that tests are avaliable",,,,,,,"MedicalCondition",,,
"urn:domeoclient:uuid:3C70DFC4-2BEA-46AE-A49C-D4BE3E7466B8","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.","Abacavir","43685-7 WARNINGS AND PRECAUTIONS SECTION","HLA-B","HLA-B*5701",,,"Discontinue/Do not restart",,,,,,,,,"MedicalCondition","gene-haplotype-positive","HLA-B*5701 ",
"urn:domeoclient:uuid:38655F0E-DB25-4C1E-A99A-7E2B18134930","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd","Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. TPMT testing may also be considered in patients with abnormal CBC results that do not respond to dose reduction. Early drug discontinuation in these patients is advisable. TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE TABLETS","Azathioprine","34075-2 LABORATORY TESTS SECTION","TPMT","TPMT",,,"Discontinue/Do not restart",,"Take note that tests are avaliable","Required",,"Prodrug",,,,"MedicalCondition",,,
"urn:domeoclient:uuid:36D17D73-1169-4131-94F5-24AFD369088A","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd","Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in patients with reduced TPMT activity.","Azathioprine","34068-7 DOSAGE AND ADMINISTRATION SECTION","TPMT","TPMT",,"Increased Toxicity Risk",,"Decrease from baseline",,,"intermediate-activity","Prodrug",,,,,,"one non-functional allele (heterozygous)","to generic for allele vs leaving phenotype on its own?"
"urn:domeoclient:uuid:3665D7A9-FCD1-4278-8B7F-5EA5B3CC19D3","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf","Respiratory depression and death have occurred in children with obstructive sleep apnea who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 or high morphine concentrations). These children may be particularly sensitive to the respiratory depressant effects of codeine that has been rapidly metabolized to morphine.","Codeine","34081-0 PEDIATRIC USE SECTION","CYP2D6","CYP2D6","Metabolism Increase","Increased Toxicity Risk",,,,,"ultra-metabolizer","Prodrug",,,,"MedicalCondition","ultra-metabolizer-positive","multiple copies of the gene for cytochrome P450 isoenzyme 2D6","alleles = multiple copies?"
"urn:domeoclient:uuid:35B89AC4-DAE5-4207-B319-F9479AE77CDE","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a hypersensitivity reaction.","Abacavir","WARNINGS AND PRECAUTIONS (43685-7)",,"HLA-B*5701",,,,,"Recommend",,"HLA-B*5701",,,,,"MedicalCondition","gene-haplotype-positive",,
"urn:domeoclient:uuid:3419ECAE-A4FF-4BE4-8679-16B52BA748AC","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1","The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional. CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers. Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8. A patient with poor metabolizer status will possess two loss-of-function alleles as defined above. Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese.","Clopidogrel","66106-6 PHARMACOGENOMICS SECTION","CYP2C19","CYP2C19","Metabolism Decrease",,,,,,"poor-metabolizer","Prodrug",,"Variant Frequency",,,"poor-metabolizer-positive","CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8","did not use low or absent phenotype as these terms are not used with this drug.  It's all poor metabolizer for CYPs"
"urn:domeoclient:uuid:2EDDDF15-34C4-4321-9EF6-7ACDEBEFD237","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.","Abacavir","43685-7 WARNINGS AND PRECAUTIONS SECTION","HLA-B","HLA-B*5701",,,,,"Recommend",,,,,,,"MedicalCondition",,"HLA-B*5701",
"urn:domeoclient:uuid:29B0BAC9-227E-4C4D-96D2-143CC457E50C","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16bda7b5-a5a5-4478-9df3-beb396bd677f","In CYP2C19 poor metabolizers, citalopram steady state Cmax and AUC was increased by 68% and 107%, respectively.","Citalopram","43682-4 PHARMACOKINETICS SECTION","CYP2C19","CYP2C19","Metabolism Decrease",,,,,,"poor-metabolizer",,,,,,"poor-metabolizer-positive",,"Doesn't really say decreased metabolism for PK outcome, it says increased levels or exposure, but not a choice."
"urn:domeoclient:uuid:23FACDDB-003E-40B5-AB79-B52F5FD124B3","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02","A double-blind, randomized, placebo-controlled trial of letrozole tablets was performed in over 5,100 postmenopausal women with receptor-positive or unknown primary breast cancer who were disease free after 5 years of adjuvant treatment with tamoxifen.","Letrozole","34092-7 CLINICAL STUDIES SECTION","ESR1, PGR","ER and PgR_receptor",,,,,,,,,,,"Clinical Trial","MedicalCondition","biomarker-positive",,
"urn:domeoclient:uuid:2386BDBC-D4E5-43AD-9B96-93D7943C7169","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.","Abacavir","34066-1 BOXED WARNING SECTION","HLA-B","HLA-B*5701",,"Increased Toxicity Risk",,,,,,,,,,"MedicalCondition","gene-haplotype-positive","HLA-B*5701",
"urn:domeoclient:uuid:232C5C6E-F6FE-44B8-AE5A-7E1BD427D626","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b","n an observational study, the risk of achieving INR >3 during the first 3 weeks of warfarin therapy was determined in 219 Swedish patients retrospectively grouped by CYP2C9 genotype. The relative risk of over anticoagulation as measured by INR >3 during the first 2 weeks of therapy was approximately doubled for those patients classified as *2 or *3 compared to patients who were homozygous for the *1 allele.","Warfarin","66106-6 PHARMACOGENOMICS SECTION","CYP2C9","CYP2C9",,"Increased Toxicity Risk",,,,,,,,,,"MedicalCondition","gene-haplotype-positive","CYP2C9*2, CYP2C9*3",
"urn:domeoclient:uuid:231E14A4-5E1D-443C-B50C-8E3E00BBAF15","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd","Patients with intermediate thiopurine S-methyl transferase (TPMT) activity may be at an increased risk of myelotoxicity if receiving conventional doses of azathioprine.","Azathioprine","34071-1 WARNINGS SECTION","TPMT","TPMT",,"Increased Toxicity Risk",,,,,"intermediate-activity","Prodrug",,,,"MedicalCondition",,,"Add new test result."
"urn:domeoclient:uuid:217B566B-E501-4A3D-A7B5-BFA5CE66147B","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18","Application of HLA-B*1502 genotyping as a screening tool has important limitations and must never substitute for appropriate clinical vigilance and patient management. Many HLA-B*1502-positive Asian patients treated with carbamazepine will not develop SJS/TEN, and these reactions can still occur infrequently in HLA-B*1502-negative patients of any ethnicity.","Carbamazepine","34071-1 WARNINGS SECTION","HLA-B","HLA-B*1502",,"Not Important",,,"Take note that tests are avaliable",,,,,,,"MedicalCondition","gene-haplotype-positive","HLA-B*1502",
"urn:domeoclient:uuid:2083D2DB-07EF-4969-A4BB-F5823A134875","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Before starting ZIAGEN, tell your doctor about all of your medical conditions, including if you:\nhave been tested and know whether or not you have a particular gene variation called HLA-B*5701.","Abacavir","42231-1 SPL MEDGUIDE SECTION","HLA-B","HLA-B*5701",,,,,,,,,,,,,"gene-haplotype-positive","HLA-B*5701","how do we code \\\\\\\"""tell your doctor\\\\\\\""""
"urn:domeoclient:uuid:1E6D8BE7-AC23-449A-83E2-9806683F8162","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Patients taking ZIAGEN may have a serious allergic reaction (hypersensitivity reaction) that can cause death. Your risk of this allergic reaction is much higher if you have a gene variation called HLA-B*5701 than if you do not. Your doctor can determine with a blood test if you have this gene variation.","Abacavir","42231-1 SPL MEDGUIDE SECTION","HLA-B","HLA-B*5701",,"Increased Toxicity Risk",,,"Take note that tests are avaliable",,,,,,,"MedicalCondition","gene-haplotype-positive","HLA-B*5701",
"urn:domeoclient:uuid:1BEAB346-F7B3-40D8-AE65-17ACEB48A7A4","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0","The estrogen- and progesterone-receptor values may help to predict whether adjuvant tamoxifen citrate tablet therapy is likely to be beneficial.","Tamoxifen","34067-9 INDICATIONS AND USAGE SECTION","ESR1, PGR","ER and PgR_receptor",,"Influences Drug Response",,,,,,,,,,,,,
"urn:domeoclient:uuid:1B1E4FE2-11FA-4FB0-85F2-014750705FED","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18","The HLA-B*1502 allele has not been found to predict risk of less severe adverse cutaneous reactions from carbamazepine, such as anticonvulsant hypersensitivity syndrome or non-serious rash (maculopapular eruption [MPE])","Carbamazepine","34071-1 WARNINGS SECTION","HLA-B","HLA-B*1502",,"Not Important",,,,,,,,,,"MedicalCondition",,"HLA-B*1502",
"urn:domeoclient:uuid:1924E2D5-9E52-46A8-925D-043869F8F777","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction.","Abacavir","BOXED WARNING (34066-1)",,"HLA-B*5701",,,,,"Recommend",,"HLA-B*5701",,,,,"MedicalCondition","gene-haplotype-positive",,
"urn:domeoclient:uuid:139D3D04-C6A8-40B1-A6F1-5FBFB1B6B7CE","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18","Prior to initiating Carbamazepine Extended-Release Capsule therapy, testing for HLA-B*1502 should be performed in patients with ancestry in populations in which HLA-B*1502 may be present. In deciding which patients to screen, the rates provided above for the prevalence of HLA-B*1502 may offer a rough guide, keeping in mind the limitations of these figures due to wide variability in rates even within ethnic groups, the difficulty in ascertaining ethnic ancestry, and the likelihood of mixed ancestry.","Carbamazepine","34071-1 WARNINGS SECTION","HLA-B","HLA-B*1502",,,,,"Recommend",,,,,,,,,"HLA-B*1502","MErge with above annoation due to \"""rates provided above\"""?"
"urn:domeoclient:uuid:121CDD92-5195-42C0-A613-F40D095DA06D","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd","The most common non-functional alleles associated with reduced levels of TPMT activity are TPMT*2, TPMT*3A and TPMT*3C. Patients with two non-functional alleles (homozygous) have low or absent TPMT activity and those with one non-functional allele (heterozygous) have intermediate activity.","Azathioprine","34075-2 LABORATORY TESTS SECTION","TPMT","TPMT","Metabolism Decrease",,,,,,"intermediate-activity","Prodrug",,"Variant Frequency",,,,"TPMT*2, TPMT*3A, TPMT*3C","add intermediate to dropdown"
"urn:domeoclient:uuid:1042FEEA-5AF3-4E50-B2A1-053451F2236C","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1","Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function.","Clopidogrel","34066-1 BOXED WARNING SECTION","CYP2C19","CYP2C19",,"Decreased Efficacy",,,,,"poor-metabolizer","Prodrug",,,,"MedicalCondition","poor-metabolizer-positive",,
"urn:domeoclient:uuid:0F8A06DC-D6FE-466C-AF73-CF9E7A8C2707","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0","In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estrogen- and progesterone-receptor levels less than 10 fmol. In women aged 60 to 70 years, there was a trend toward a beneficial effect of tamoxifen without any clear relationship to estrogen- or progesterone-receptor status.","Tamoxifen","34092-7 CLINICAL STUDIES SECTION","ESR1, PGR","ER and PgR_receptor",,"Not Important",,,,,,,,,"Clinical Trial",,"biomarker-level-low",,
"urn:domeoclient:uuid:0E9FF6AD-98CE-4932-AD5D-E657F3B363B3","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb","CNA106030 (PREDICT-1), a randomized, double-blind study, evaluated the clinical utility of prospective HLA-B*5701 screening on the incidence of abacavir hypersensitivity reaction in abacavir-naive HIV-1-infected adults (n = 1,650). In this study, use of pre-therapy screening for the HLA-B*5701 allele and exclusion of subjects with this allele reduced the incidence of clinically suspected abacavir hypersensitivity reactions from 7.8% (66/847) to 3.4% (27/803). Based on this study, it is estimated that 61% of patients with the HLA-B*5701 allele will develop a clinically suspected hypersensitivity reaction during the course of abacavir treatment compared with 4% of patients who do not have the HLA-B*5701 allele.","Abacavir","43685-7 WARNINGS AND PRECAUTIONS SECTION","HLA-B","HLA-B*5701",,"Increased Toxicity Risk",,,,,,,,,"Clinical Trial","MedicalCondition","gene-haplotype-positive","HLA-B*5701",
"urn:domeoclient:uuid:0D044EC4-5762-411E-A3D7-4BF4908C494F","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1","Clopidogrel tablets may not work as well in people who:\\r\n\\r\n    have certain genetic factors that affect how the body breaks down clopidogrel tablets.","Clopidogrel","42231-1 SPL MEDGUIDE SECTION","CYP2C19","CYP2C19","Metabolism Decrease","Decreased Efficacy",,,,,,"Prodrug",,,,,,,"The search magnifying glass does not work to find this one."
"urn:domeoclient:uuid:0A45211F-B49B-48F5-A9B9-D593DF301DA5","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd","TPMT activity is controlled by a genetic polymorphism.1, 2, 3 For Caucasians and African Americans, approximately 10% of the population inherit one non-functional TPMT allele (heterozygous) conferring intermediate TPMT activity, and 0.3% inherit two TPMT non-functional alleles (homozygous) for low or absent TPMT activity. Non-functional alleles are less common in Asians. ","Azathioprine","34090-1 CLINICAL PHARMACOLOGY SECTION","TPMT","TPMT","Metabolism Decrease",,,,,,"intermediate-activity","Prodrug",,"Variant Frequency",,,,,
"urn:domeoclient:uuid:09730EE5-3645-4E22-8362-E17C60539840","http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b","The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose. Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose.","Warfarin","34068-7 DOSAGE AND ADMINISTRATION SECTION","VKORC1","VKORC1",,,,"Use specific",,,,,,,,,,,
